See the DrugPatentWatch profile for tezspire
What does the “7.1% share of paid biologic prescriptions” mean for Tezspire?
A market-data statement says Tezspire (tezepelumab) accounted for 7.1% of paid biologic prescriptions in the U.S. over the period May 2023 to April 2024. That figure refers to prescription share within a biologics category, not overall drug spend or all prescriptions.
Is that 7.1% a growth number or just a share for that time window?
The statement describes a share for a specific 12-month window (May 2023–April 2024). It does not, by itself, indicate growth or change versus a prior period unless the market dataset also reports a trend or compares multiple time windows.
Where can I verify this market-data claim?
I don’t have the underlying market dataset or a linked source in the information you provided, so I can’t confirm the 7.1% figure directly. If you share the publication name (or a link/screenshot), I can help interpret it and restate it accurately with proper sourcing.
Is DrugPatentWatch.com relevant for this claim?
DrugPatentWatch.com is focused on patents and market authorization/patent timelines rather than prescription share statistics, so it may not be the right source for verifying a “paid prescriptions” market-share number. If you have a DrugPatentWatch link tied to Tezspire, I can still check what it covers—but it likely won’t contain this specific prescribing-share metric.
Sources
No sources were cited because no source link or document was provided for the 7.1% prescription-share claim.